FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Börse Stuttgart 02:27:39 2024-05-24 pm EDT | ||
| 0.43 EUR | 0.00% |
|
| Current month | -15.69% | ||
| 1 month | -21.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 0.43 | 0.00% |
| 24-05-23 | 0.43 | -6.52% |
| 24-05-22 | 0.46 | -2.13% |
| 24-05-21 | 0.47 | 0.00% |
| 24-05-20 | 0.47 | -4.08% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 02:27 pm EDT
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MB14DT |
| ISIN | DE000MB14DT3 |
| Date issued | 2022-12-01 |
| Strike | 1,250 kr |
| Maturity | Unlimited |
| Parity | 96.35 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.89 € |
|---|---|
| Lowest since issue | 0.43 € |
| Spread | 0.01 € |
| Spread % | 2.27% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
928.8
DKK
Average target price
909.2
DKK
Spread / Average Target
-2.11%
- Stock Market
- Certificates
- Certificat
